格隆汇2月11日丨漳州发展(000753.SZ)公布，公司全资子公司福建漳发建设有限公司（简称漳发建设） 就漳州市常山竹港溪防洪排涝提升改造工程（一期）设计施工总承包（EPC）—生态修复工程专业分包 （标段一）与福建大农景观建设有限公司（简称大农景观）签署《建设工程施工专业分包合同》，合同 价款为2,493.0388万元。鉴于大农景观为公司控股股东福建漳龙集团有限公司（简称漳龙集团）的下属 企业，上述交易构成关联交易。 ...

经公司第二届董事会提名委员会进行任职资格审查后，公司于2026年2月11日召开第二届董事会第二十 二次会议，审议通过了《关于聘任公司总经理的议案》，同意聘任陈健旭先生担任公司总经理，任期自 本次董事会审议通过之日起至第二届董事会任期届满之日止。 格隆汇2月11日丨南新制药（维权）(688189.SH)公布，公司董事会于近日收到张世喜先生提交的书面辞 职报告，张世喜先生因工作调整原因申请辞去公司总经理职务。根据《公司法》《公司章程》的有关规 定，张世喜先生的辞职报告自送达董事会之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、 董事会战略委员会召集人职务。 ...

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) aims to optimize its asset structure and improve the quality of asset operations by transferring part of its accounts receivable through a public listing [1] Group 1: Asset Transfer Details - The company plans to transfer accounts receivable with a total book balance of 489.784 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 459.7945 million yuan, resulting in a book value of 29.9895 million yuan for the receivables being transferred [1] - The asset transfer is expected to enhance the company's operational development and protect the legal rights of the company and all shareholders [1] Group 2: Transaction Process - The transaction will be conducted through a public listing, and no transaction agreement has been signed yet [1] - It is currently unclear whether the transaction will constitute a related party transaction [1] - If the determined buyer through the public listing process is a related party, the company will follow the necessary review procedures for related party transactions [1]

Core Viewpoint - The company, through its subsidiaries, is participating in a national centralized procurement process for pharmaceuticals, which could enhance its market share and brand influence if selected products are confirmed and contracts are signed [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries and a controlling subsidiary are involved in the national centralized procurement for expiring drug agreements [1] - The procurement office announced the proposed selection results for the procurement on February 10, 2026 [1] Group 2: Potential Impact - If the proposed selected products are confirmed and contracts are signed, it will help the company expand sales of related products [1] - The successful procurement will ensure that medical institutions prioritize the selected drugs, which is expected to positively impact the company's future operating performance [1]

Core Viewpoint - Huatai Technology (603679.SH) announced a share reduction by one of its actual controllers, Wang Shaorong, through block trading, resulting in a change in shareholding percentage due to capital changes from convertible bond conversions [1] Group 1 - Wang Shaorong reduced her shareholding by 1.916 million shares between February 6, 2026, and February 10, 2026 [1] - Following the reduction and the impact of convertible bond conversions, the combined shareholding percentage of Wang Shaorong and her concerted parties decreased from 33.80% to 32.55% [1] - The change in equity holding triggered a shift that touched the 1% threshold [1]

注射用青霉素钠适用于敏感菌所致的各类感染，如脓肿、菌血症、肺炎和心内膜炎。其中青霉素为以下 感染的首选药物：溶血性链球菌感染；肺炎链球菌感染；不产青霉素酶葡萄球菌感染；炭疽；破伤风、 气性坏疽等梭状芽孢杆菌感染；梅毒（包括先天性梅毒）；钩端螺旋体病；回归热；白喉；青霉素与氨 基糖苷类药物联合用于治疗草绿色链球菌心内膜炎。 格隆汇2月11日丨白云山(600332.SH)公布，公司控股子公司广州白云山天心制药股份有限公司（称"天 心制药"）收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用青霉素钠0.96g （160万单位）已通过仿制药质量和疗效一致性评价。 ...

格隆汇2月11日丨科瑞技术(002957.SZ)公布，新加坡科瑞技术计划通过集中竞价、大宗交易等深圳证券 交易所认可的合法方式减持公司股份。新加坡科瑞技术计划减持不超过420万股，即不超过公司总股本 的1.0004%。 李单单女士计划通过集中竞价方式减持公司股份。李单单女士计划减持不超过12.42万股，即不超过公 司总股本的0.0296%。 饶乐乐先生计划通过集中竞价方式减持公司股份。饶乐乐先生计划减持不超过6万股，即不超过公司总 股本的0.0143%。 华苗投资计划通过集中竞价、大宗交易等深圳证券交易所认可的合法方式减持公司股份。华苗投资计划 减持不超过420万股，即不超过公司总股本的1.0004%。 鹰诺投资计划通过集中竞价、大宗交易等深圳证券交易所认可的合法方式减持公司股份。鹰诺投资计划 减持不超过400万股，即不超过公司总股本的0.9528%。 ...

格隆汇2月11日丨东南网架(002135.SZ)公布，近日收到招标单位杭州萧山城市有机更新有限公司发来的 《中标通知书》，确定公司与杭州市建筑设计研究院股份有限公司组成的联合体为"杭政储出（2025） 101号商业综合体新建项目EPC工程总承包项目"的中标单位。本项目中标总金额为人民币4.84亿元。 ...

Group 1 - The core point of the article is that Okoyi (688308.SH) announced a plan for its shareholder, Leqing Dehui, to reduce its stake in the company by up to 1.00% of the total shares, which amounts to a maximum of 1.58 million shares [1] - The share reduction will take place within three months after the announcement, starting 15 trading days from the date of disclosure [1] - The reduction will be executed through centralized bidding, with a limit that the total number of shares sold in any consecutive 90-day period does not exceed 1% of the company's total shares [1]

Group 1 - The company plans to acquire 70% equity of Huilian Electronics for no more than RMB 700 million, aiming to gain control over the company [1] - The funding for the acquisition will come from the company's own funds and merger loans [1] - The company also intends to acquire 70% equity of WINWIN HITECH (THAILAND) CO., LTD. for no more than RMB 28 million to address competition issues and develop overseas markets [1] Group 2 - Huilian Electronics specializes in PCB tools, cutting tools, and precision parts, recognized as a national-level "little giant" in the PCB tool sector and a champion enterprise in Henan province [2] - The acquisition will include PCB tools and related assets, with the major shareholders cooperating to divest non-PCB tool business assets [2] - This transaction is a strategic move to enhance the company's comprehensive layout in cutting tools and accelerate the domestic substitution of PCB tools, strengthening the integration of the hard alloy industry chain [2]